$6.50
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Envoy Medical, Inc. is a hearing health company, which engages in providing medical technologies across the hearing loss spectrum. The company is headquartered in White Bear Lake, Minnesota and currently employs 43 full-time employees. The company went IPO on 2021-03-02. The firm is engaged in providing medical technologies across the hearing loss spectrum, all designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they require. Its hearing solutions include hearing aids, middle ear implants, bone conduction devices and cochlear implants. The bone conduction hearing device has two components: an external component and a surgically implanted fixture placed in the bone behind the ear. Its bone conduction hearing device offers amplification without ear mold in the ear. Its hearing aids are devices that amplify sound for those with mild to moderate hearing loss. Its Esteem is a fully implanted active middle ear implant designed to improve the hearing of adults diagnosed with moderate to severe sensorineural hearing loss. Cochlear implants are a solution for people with moderate-to-profound sensorineural hearing loss.
Country

US

CEO

Mr. Brent Lucas

IPO date

2021

Employees

43

ISIN

US29415V1098

Key stats

Open

$5.11

Volume

49.95K

Market cap

$46.09M

Prev. close

$6.50

Impl / hst vl

-

Open interest

$0.00

$4.72

Day’s Range

$6.60

$0.36

52W Range

$0.95

Valuation

33
Valuation score
Overvalued
P/E
-
P/S
222.65
P/B
13.95
Current ratio
1.73
Debt / Equity
-5.96
ROE
-153.49%
Gross margin
-445.10%
Income growth
27.56%
FCF growth
-9.88

Analysts estimates

Consensus rating
Buy

The average rating from top 5 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$2.21
The top 5 analysts forecasts that 12-month price may decrease by 66.00%, with a low of $2.02 and a high of $2.63
$2.02
Low
$2.21
Avg
$2.63
High
Current price

Earnings

Q2 ‘26 revenue
$51.00K
Q2 ‘26 net income
-$7.27M
Revenue
Net income
Previous EPS
-$0.07
Estimate EPS
-$0.07
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply